Julie Prigent is a Project leader R&D – Principal Scientist at BIOMUNEX. Prior to joining the company, she worked at H-Immune and HiFiBio therapeutics (Paris, FR) in identifying targets of interest in Immuno-oncology field. Further, she was involved in developing therapeutic antibodies, from discovery to CMC, with a focus on targeting Tregs to restore anti-tumor immunity. She has a strong immunology and antibody engineering background acquired during her PhD at CEA (Saclay, FR) where she worked on identifying therapeutic antibodies against toxins in the context of the fight against Bioterrorism. She studied the evolution of broad neutralizing antibodies in HIV patients during her post-doctoral fellow at Pasteur Institute. She is 1st author in several articles in scientific journals but also co-inventor of a recent patent.